C/EBPβ is a key transcription factor of ox-LDL inducing THP-1 cells to release multiple pro-inflammatory cytokines

[1] Libby P(2021)The changing landscape of atherosclerosis Nature 592 524-533

[2] Everett Brendan M(2017)Anti-inflammatory therapy with canakinumab for atherosclerotic disease N Engl J Med 377 1119-1131

[3] MacFadyen Jean G(2020)Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS Trial J Am Coll Cardiol 76 1660-1670

[4] Thuren T(2019)Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis Eur Heart J 41 2153-2163

[5] Libby P(2011)The nuclear factor—kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease Thromb Res 128 117-123

[6] Glynn Robert J(2012)Caspase-1 deficiency decreases atherosclerosis in apolipoprotein E-Null mice Can J Cardiol 28 222-229

[7] Ridker PM(2014)Transcription factor cooperativity in early adipogenic hotspots and super-enhancers Cell Rep 7 1443-1455

[8] Pamukcu B(2015)CCAAT/enhancer binding protein β in relation to ER stress, inflammation, and metabolic disturbances Biomed Res Int 2015 324815-179

[9] Lip GYH(2016)C/EBPβ in bone marrow is essential for diet induced inflammation, cholesterol balance, and atherosclerosis Atherosclerosis 250 172-607

[10] Shantsila E(2008)Ox-LDL induces monocyte-to-macrophage differentiation in vivo: Possible role for the macrophage colony stimulating factor receptor (M-CSF-R) Atherosclerosis 196 598-667

[1] Libby P(2021)The changing landscape of atherosclerosis Nature 592 524-533

[2] Everett Brendan M(2017)Anti-inflammatory therapy with canakinumab for atherosclerotic disease N Engl J Med 377 1119-1131

[3] MacFadyen Jean G(2020)Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS Trial J Am Coll Cardiol 76 1660-1670

[4] Thuren T(2019)Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis Eur Heart J 41 2153-2163

[5] Libby P(2011)The nuclear factor—kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease Thromb Res 128 117-123

[6] Glynn Robert J(2012)Caspase-1 deficiency decreases atherosclerosis in apolipoprotein E-Null mice Can J Cardiol 28 222-229

[7] Ridker PM(2014)Transcription factor cooperativity in early adipogenic hotspots and super-enhancers Cell Rep 7 1443-1455

[8] Pamukcu B(2015)CCAAT/enhancer binding protein β in relation to ER stress, inflammation, and metabolic disturbances Biomed Res Int 2015 324815-179

[9] Lip GYH(2016)C/EBPβ in bone marrow is essential for diet induced inflammation, cholesterol balance, and atherosclerosis Atherosclerosis 250 172-607

[10] Shantsila E(2008)Ox-LDL induces monocyte-to-macrophage differentiation in vivo: Possible role for the macrophage colony stimulating factor receptor (M-CSF-R) Atherosclerosis 196 598-667